1540P - Implementation of an interdisciplinary molecular tumor board in managing of advanced stage breast cancer

Date 10 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Sorin Armeanu-Ebinger
Citation Annals of Oncology (2016) 27 (6): 526-544. 10.1093/annonc/mdw392
Authors S. Armeanu-Ebinger1, D. Döcker1, A. Kopic2, S. Brucker3, D. Wallwiener3, U. Martens4, C. Kyzirakos1, M. Menzel1, A. Rinkleb1, S. Biskup1
  • 1Tumor Diagnostics, CeGaT GmbH, 72076 - Tübingen/DE
  • 2-, Private Oncological Daily Clinic, 70579 - Stuttgart/DE
  • 3Universitäts-frauenklinik, University Clinic Tübingen, 72076 - Tübingen/DE
  • 4Klinik Für Innere Medizin Iii: Hämatologie, Onkologie, Palliativmedizin, SLK-Kliniken Heilbronn GmbH, Heilbronn/DE



Screening of somatic mutations in tumors is included in modern studies in oncology to test the efficiency of a particular drug expected to target the detected mutations. In so called “Umbrella” trials a set of preselected drugs are tested in cancer patients with different cancer types with distinct mutations. Despite of promising results of different studies based on molecular testing, the impact of comprehensive screening approaches is still underestimated. In a personalized medicine the molecular tumor analyses has to complement other diagnostics and enable up-to-date therapy such as targeted therapies, immunotherapies, and others.


We compared a dataset of 25 breast cancer cases who had previously undergone CeGaT somatic tumor panel (NGS-based panel diagnostics comprising 649 tumor-related genes) or tumor exome diagnostics. All cases were discussed in an interdisciplinary tumor board composed by gynecologists, oncologists, clinical and molecular geneticists. Among others, issues such as clinical relevance of the molecular report in the context of the individual clinical setting were discussed retrospectively.


In an adjuvant setting, standard/guideline therapies were considered the best approach. In locally advanced tumors, relapse or metastatic disease, the molecular report was considered extremely relevant, either consistent with clinical decisions or enabling new approaches, including targeted or immunologic therapies, but also selected chemotherapy. Only in 1/25 cases (4 %), no therapeutically relevant somatic mutation could be detected. We present select examples of cases, in which the therapeutic approach would be re-considered retrospectively.


The retrospective evaluation resulted in the implementation of a monthly interdisciplinary molecular tumor board discussing current patients and prospective approaches. All patients with locally advanced tumors, relapse or metastases are offered comprehensive molecular testing and comprehensive individual evaluation of therapeutic approaches.

Clinical trial identification

Legal entity responsible for the study



CeGaT GmbH


S. Armeanu-Ebinger, D. Döcker, C. Kyzirakos, M. Menzel, A. Rinkleb: Employed at CeGaT GmbH, which provides molecular tumor diagnostics. All other authors have declared no conflicts of interest.